Member Info for Mikemine

I know little about the finer arts of day trading but I have no idea why the SP is at such a low level nor why people are selling. They can't have made anything by selling at these levels and to my mind the share is a screaming buy. Yet there is still selling going on. Can anybody explain the conundrum.

I must admit I hadn't seen this before Marty posted it this morning. It's 9 months old I believe but the message is strong. I'd like to see it updated now the latest news is out. Worth a viewing to remind us where RENX is going, not to mention the cost of getting there.

https://www.youtube.com/watch?v=Mdvnf7qS464

From an investment view, 14p is a no brainer IMHO but day traders might see it differently.

What idiot in Polar ordered the sell off they should ask themselves. Yes they hit the day's high but it was obvious on Monday that the momentum was strongly behind further increases this week which would have given Polar a bigger return.

Thats 2 big chunks of shares sold and out of the way. Unless Polar are getting rid of their remaining stock, the buying momentum will hopefully continue. Certainly at this level the SP looks tasty IMHO.

I'm not sure what relevance this history has to the present day Marty but RENX is still listed in the US and have pulled off a very good deal. Tempus are not known for scalping small companies the have links with so I assume the terms of the deal will leave RENX with decent profits. It's like Dodge City out there at the moment but let the Market settle a bit to let the day traders go elsewhere and the fundamentals will propel the SP IMHO. To what level is anybody's guess but it won't be at today's ending price I bet. Should be interesting and hopefully profitable tomorrow. Sleep well.

If Polar have finished dumping, the SP should recover tomorrow as there are plenty of buyers out the, and why not? Such is AIM. As well as driving PIs mad, the management must be out of their minds. Do a great deal, transformational even, and the SP ends up about where it started. What more can they do?

The holdings RNS looks like a big vote of confidence to me.

What does that code mean?

The inevitable sell off by day traders but, for longer term holders, the prospects are fantastic. The deal opens up everything for RENX. It's a big deal without doubt. No point in talking multiples but the value of the deal is not in the SP at the moment IMHO.

2 excellent profit affecting RNSs and the SP goes up 10% and that sums up AIM. AIM is finished and the quicker IES gets on to Nasdaq the better.

Just a guess but they've got over one hurdle, proof of concept, and then proof of acceptance by clinicians and now they've got to prove the product can be commercialised.. After that the company looks attractive with all the hard work done. Have they contacted larger players? I really have no way of knowing but I suspect that the field they are in is quite small and what they are doing and have done will be on somebody's radar IMHO. Patience as ever.

Talking without any local knowledge, I can't imagine a salesperson's costs are less that $100K pa if you include healthcare and other employer's costs. Hire 5 and that's another half million on to top of your on costs. Recovering those costs don't come immediately as there is training and familiarisation with the internal workings of the company, industry and scientific work areas. What do you do as a CEO? Do you go for broke or take on a couple of guys on to see how well that goes and maybe add another couple when things are taking the upward swing you are hoping and planned for? A tricky one.

If VRCI are hoping for a buyout, getting a well oiled system in place to indicate to a potential buyer that expansion might be quite easy with more resources, might be be the way to go. Without sitting in the boardroom we can only guess.

Something spooked me which challenged the veracity of my post but that has gone away and proved groundless. What hasn't gone away is my misspelling of Clarava. Apologises. I guess that, as TF have made their stage payments, they are satisfied with their research to date. All to play for there.

I might have got it wrong about Calvary linking with TF. I'll look into my assumption. In the meantime ignore me.

Thermo fisher are a big company and as such are one of the plodders. I can't tell if they are satisfied with the development of Calvara before they commercialise yet. Once they are satisfied they have a product they have that will not harm their reputation by not living up to their promise, their salesforce will take it to the market with gusto I'm sure. Salesmen like nothing better than a new story to tell.

I'll look in to it a bit more but, in the meantime ,VRCI have got a bundle of cash from them and free development to boot. Not bad for a tiddler.

Some good points Bobby. I can't imagine that VIRCI is not on the radar of some bigger concern and, as you say, they might be waiting for greater adoption to be more certain. Personally, if I was in charge of such a company, the commercialisation to date, with one hospital protocol in the bag, would tempt me to come in with a killer bid, even at 100% premium, while the valuation is at this low level. Putting bigger resources behind Tutivia would propel it big time IMHO.

Talking of resources, their fundraise was minimal IMHO and I'm sure SB would have gone for more. The financial market out there in the UK for this type of project is dire at the moment as I expect you know so that could be holding them back.

I can't see any serious completion out there atm but there's always that possibility. CareDX is in that field but their product can't match Tutivia in any way.

It really is down to VRCI's progress in the next 6 months. They've increased their sales force but these guys need education in the product and scientific workings so won't be effective for a while. They have some money and, as I've said before, they have to be given space and time to prove themselves. In the meantime it really doesn't help the SP to be endlessly critical of the CEO and the way the company is being run. People are entitled to their opinions but negativity is doing nobody any good. Just my opinion of course.

Https://www.google.com/search?client=safari&rls=en&q=vox+interview+with+sara+barrington&ie=UTF-8&oe=UTF-8#fpstate=ive&vld=cid:12520c72,vid:gNsAJF2HECo,st:0 I found this interview which I assume is the one to which you refer.

If you are only interested in revenue projection etc, look elsewhere. There is a bit about the size of the addressable market but mainly it is about how the company is approaching that market and some of the feedback from clinicians. To me it spoke volumes about the need of clinicians to have test to predict and indicate likely reactions to their transplants. They seem to be operating blind at the moment and anything like Tutivia would be most welcome. Barrington and her team come across as thoughtful and competent so, to me, they need to be given time to prove themselves. Patience needed here as always.

Tutivia is not 100% accurate and has never been claimed to be but it's a whole lot better than what clinicians have in their locker at the moment and it will probably get better with the feedback info. from said clinicians. It is not that unusual to have a less that 100% accurate test in general use. The PSA test for cancer of the prostate, for example, is notoriously unreliable but is used prolifically in the NHS. While nothing better comes along, I can see Tutivia being the go-to test for clinicians in the kidney transplant field which means lots sales for VRCI. Already 2 hospitals have included it in their protocols and I'm sure there will be more to follow especially as the new funding will allow a ramping up of the sales force. It's up to Barrington now to show us her ability to expand the company to increase the numbers. She has the money and she now needs the time. Patience as ever.

Lunglife was on the rocks when Barrington was brought in to turn it around which she did. She then passed on the CEO position to the present CEO around a couple of years ago. I'm not here to defend Barrington but get the facts right.